Amgen reported second-quarter 2026 adjusted earnings of $6.29 per share, beating the Zacks Consensus Estimate of $5.60, and raised its full-year guidance. Total revenues increased 10% to $10.1 billion, surpassing the consensus estimate of $9.44 billion, driven by a 9% rise in product sales to $9.54 billion. Key growth drivers, including Repatha, Evenity, Tezspire, and oncology and rare disease drugs, grew 26% year over year and represented almost 70% of total product sales. The company lifted its 2026 revenue outlook to a range of $38.2 billion to $39.4 billion and adjusted earnings guidance to $22.30 to $23.50 per share, citing strong first-half execution. However, sales of legacy drugs Prolia and Xgeva declined sharply due to biosimilar competition following patent expirations in 2025.
Amgen IncAmgen beat Q2 earnings estimates and raised 2026 guidance.
AstraZeneca PLC
Eli Lilly and Company
Affiliated Managers Group, Inc.
Novo Nordisk A/S